CONCLUSIONS: These results suggest that BMSCs modified with PDE5-RNAi treatment can enhance the recovery of erectile function in aged rats. METHODS: Thirty-six Lewis rats, aged 10-12 weeks, were divided into five groups: sham operation, bilateral cavernous nerve crush injury and bilateral internal pudendal bundle ligation without treatment (control), injury with MSC injection, injury with LESWT and MSC, injury with MSC and PDE5i, injury with LESWT, PDE5i, and MSC (n¼6 rats/group). The groups receiving MSCs were given a one-time intracavernosal injection of bone marrow-derived MSCs (2 million in 100ml of normal saline) at the time of injury. Forty-eight hours after injury groups were started on three times weekly LESWT (1000 pulses at 0.06 mJ/mm2 and 3Hz) or sildenafil was given by mouth mixed into daily drinking water at 5-20 mg/kg/day (water intake ad libitum) with a 1% sucrose additive, for four weeks. Following one week washout period (week 5), intracavernous pressure (ICP) was assessed at week 6 as a final outcome measure.
INTRODUCTION AND OBJECTIVES: Erectile dysfunction (ED)
following trauma is challenging as traditional therapies are often ineffective. Low-energy shockwave therapy (LESWT) has shown promise in recovery of erectile function. This study aimed to determine whether the combination of mesenchymal stem cells (MSC), LESWT, and phosphodiesterase 5-inhibitors (PDE5i) would result in improved erectile function.
METHODS: Thirty-six Lewis rats, aged 10-12 weeks, were divided into five groups: sham operation, bilateral cavernous nerve crush injury and bilateral internal pudendal bundle ligation without treatment (control), injury with MSC injection, injury with LESWT and MSC, injury with MSC and PDE5i, injury with LESWT, PDE5i, and MSC (n¼6 rats/group). The groups receiving MSCs were given a one-time intracavernosal injection of bone marrow-derived MSCs (2 million in 100ml of normal saline) at the time of injury. Forty-eight hours after injury groups were started on three times weekly LESWT (1000 pulses at 0.06 mJ/mm2 and 3Hz) or sildenafil was given by mouth mixed into daily drinking water at 5-20 mg/kg/day (water intake ad libitum) with a 1% sucrose additive, for four weeks. Following one week washout period (week 5), intracavernous pressure (ICP) was assessed at week 6 as a final outcome measure.
RESULTS: Pelvic neurovascular injury resulted in a significant decrease in erectile function as measured by maximum ICP, average ICP and change in ICP (p¼0.003, 0.001, 0.007, respectively). MSC therapy alone resulted in partial recovery (average ICP, change in ICP compared to control group, p¼0.05, 0.037). When compared to the sham group, combination LESWT and MSC resulted in partial recovery (p¼0.08). The other combination therapies tested did not show significant (p>0.05) erectile recovery.
CONCLUSIONS: MSC alone and in combination with LESWT produced partial improvement of erectile function in a rat model of pelvic nerve injury. . The fate of grafted cells, however, is poorly characterized, and it is unknown if labeling technology impacts cellular function. Thus, alongside human placental stem cells (hPSC) we aim to use a novel dual-labeling technique featuring a red fluorescent protein variant mKATE and a new codon-optimized luciferase from Renilla Reniformis (mKATE-renLUC) using a lentivirus vector. We aim to determine the effect of labeling on in vitro function in preparation for future bioluminescence-tracking following intracavernosal administration.
METHODS: To optimize the transfection protocol, different hPSC concentrations, vectors (mKATE-renLUC, GFP-FLUC), and lentivirus titers were tested. Cell viability, proliferation, migration, and paracrine effects of hPSC expressing mKATE-renLUC were examined, and compared to non-labeled cells. Paracrine effects of labeled cells were examined using an angiogenesis array. Cell survival and distribution of hPSC expressing mKATE-renLUC were monitored by IVIS imaging system in vitro.
RESULTS: Cell viability, morphology, migration, and cell proliferation of mKATE-renLUC labeled hPSC were similar to those of nonlabeled cells in vitro. Cell survival and migration of renLUC-labeled hPSC were efficiently monitored using IVIS imaging system. The angiogenesis array demonstrated similar expression of factors from both cell types.
CONCLUSIONS: This study demonstrates that dual-labeling technology using mKATE-renLUC provides a safe and effective cell tracking approach with brighter fluorophores and codon optimized luciferase. This development is promising for longer and more effective in vivo stem cell tracking after intracavernosal administration in models of ED. . 199, No. 4S, Supplement, Monday, May 21, 2018 
